Cencora, Inc. (NYSE:COR) Position Lifted by Eagle Asset Management Inc.

Eagle Asset Management Inc. grew its position in Cencora, Inc. (NYSE:COR - Free Report) by 32.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,009,454 shares of the company's stock after acquiring an additional 249,739 shares during the quarter. Cencora accounts for 1.3% of Eagle Asset Management Inc.'s portfolio, making the stock its 3rd biggest holding. Eagle Asset Management Inc. owned approximately 0.51% of Cencora worth $250,758,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of COR. Kingswood Wealth Advisors LLC bought a new position in shares of Cencora during the second quarter valued at approximately $655,000. Czech National Bank grew its position in Cencora by 8.3% in the 2nd quarter. Czech National Bank now owns 31,546 shares of the company's stock valued at $7,107,000 after acquiring an additional 2,414 shares during the last quarter. Gabelli Funds LLC purchased a new stake in Cencora in the first quarter worth $14,093,000. Mackenzie Financial Corp lifted its position in shares of Cencora by 9.9% during the second quarter. Mackenzie Financial Corp now owns 81,001 shares of the company's stock worth $18,250,000 after purchasing an additional 7,266 shares during the last quarter. Finally, HM Payson & Co. purchased a new stake in shares of Cencora during the first quarter valued at $708,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Down 0.0 %

NYSE:COR traded down $0.11 during midday trading on Friday, reaching $245.58. 428,675 shares of the stock traded hands, compared to its average volume of 1,397,838. The business has a 50-day moving average of $233.12 and a two-hundred day moving average of $231.47. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a 12-month low of $195.83 and a 12-month high of $251.56. The stock has a market capitalization of $48.39 billion, a PE ratio of 32.69, a price-to-earnings-growth ratio of 1.60 and a beta of 0.44.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. This is an increase from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio is 29.29%.

Insiders Place Their Bets

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the business's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the sale, the chairman now owns 306,752 shares in the company, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on COR shares. JPMorgan Chase & Co. raised their price target on shares of Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 21st. Bank of America reaffirmed a "neutral" rating and set a $245.00 price target (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Wells Fargo & Company boosted their price target on Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a report on Thursday, August 1st. StockNews.com downgraded Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Finally, Barclays upped their target price on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $271.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.